Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Levosimendan - AbbVie/Tenax Therapeutics

Drug Profile

Levosimendan - AbbVie/Tenax Therapeutics

Alternative Names: Daxim; ODM 109; OR-1259; Simdax

Latest Information Update: 27 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Orion
  • Developer Abbott Laboratories; AbbVie; Imperial College of Science, Technology and Medicine; Orion; Tenax Therapeutics
  • Class Antiarrhythmics; Cardiotonics; Cardiovascular therapies; Hydrazones; Nitriles; Pyridazines; Small molecules; Vasodilators
  • Mechanism of Action Calcium-binding protein modulators; Calcium-sensitising phosphodiesterase inhibitors; Potassium channel agonists; Type 3 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute heart failure
  • Phase III Amyotrophic lateral sclerosis; Chronic heart failure; Low cardiac output
  • Phase II Pulmonary hypertension
  • Discontinued Myocardial infarction; Septic shock; Stroke; Transient ischaemic attacks

Most Recent Events

  • 19 Nov 2018 Phase-II clinical trials in Pulmonary hypertension in USA (IV) (NCT03541603)
  • 14 Nov 2018 Tenax Therapeutics initiates enrolment in a phase II trial for Pulmonary hypertension in USA (IV) (NCT03624010)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top